Evidence map›Paper›PMID 18952643›Full record

GuidelineAnnals of the rheumatic diseases2009

Treatment recommendations for psoriatic arthritis.

C T Ritchlin, A Kavanaugh, D D Gladman, P J Mease, P Helliwell, W-H Boehncke, K de Vlam, D Fiorentino, O Fitzgerald, A B Gottlieb and 6 more

Abstract readConsensus StatementPractice GuidelineSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of the rheumatic diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. [Psoriatic arthritis].Innere Medizin (Heidelberg, Germany) · 2026
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

C T RitchlinClinical Immunology Research Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, New York 14642, USA. christopher_ritchlin@urmc.rochester.edu
A Kavanaugh
D D Gladman
P J Mease
P Helliwell
W-H Boehncke
K de Vlam
D Fiorentino
O Fitzgerald
A B Gottlieb
N J McHugh
P Nash
A A Qureshi
E R Soriano
W J Taylor
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion.

methodsFormal literature reviews of treatment for the most significant discrete clinical manifestations of PsA (skin and nails, peripheral arthritis, axial disease, dactylitis and enthesitis) were performed and published by members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations were drafted for each of the clinical manifestations by rheumatologists, dermatologists and PsA patients based on the literature reviews and consensus opinion. The level of agreement for the individual treatment recommendations among GRAPPA members was assessed with an online questionnaire.

resultsTreatment recommendations were developed for peripheral arthritis, axial disease, psoriasis, nail disease, dactylitis and enthesitis in the setting of PsA. In rotal, 19 recommendations were drafted, and over 80% agreement was obtained on 16 of them. In addition, a grid that factors disease severity into each of the different disease manifestations was developed to help the clinician with treatment decisions for the individual patient from an evidenced-based perspective.

conclusionsTreatment recommendations for the cardinal physical manifestations of PsA were developed based on a literature review and consensus between rheumatologists and dermatologists. In addition, a grid was established to assist in therapeutic reasoning and decision making for individual patients. It is anticipated that periodic updates will take place using this framework as new data become available.

Indexed as

AdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticEvidence-Based MedicineGlucocorticoidsHumansMalePsoriasisSeverity of Illness IndexTumor Necrosis Factor-alphaYoung AdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsGlucocorticoidsTumor Necrosis Factor-alpha

Identifiers

PMID18952643
PMCPMC2719080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.